Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors-Reference-Cited by-同舟云学术

Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors

Published:2009-03-24 Issue:6 Volume:64 Page:1165-1172
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Yamamoto Noboru,Tamura Tomohide,Yamamoto Nobuyuki,Yamada Kazuhiko,Yamada Yasuhide,Nokihara Hiroshi,Fujiwara Yutaka,Takahashi Toshiaki,Murakami Haruyasu,Boku Narikazu,Yamazaki Kentaro,Puchalski Thomas A.,Shin Eisei

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-009-0979-8.pdf

Reference27 articles.

1. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249–257

2. Ferrara N, Davis-Smyth T (1997) The biology of vascular endothelial growth factor. Endocr Rev 18:4–25

3. Veeravagu A, Hsu AR, Cai W et al (2007) Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Recent Patents Anticancer Drug Discov 2:59–71

4. Nilsson M, Heymach JV (2006) Vascular endothelial growth factor (VEGF) pathway. J Thorac Oncol 1:768–770

5. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23:1011–1027

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Phase I open-label study of cediranib plus etoposide and cisplatin as first-line therapy for patients with extensive-stage small-cell lung cancer or metastatic neuroendocrine non-small-cell lung cancer;Clinical Lung Cancer;2024-09

2. Lost in translation: Revisiting the use of tyrosine kinase inhibitors in colorectal cancer;Cancer Treatment Reviews;2022-11

3. Polypharmacology in Clinical Applications—Anticancer Polypharmacology;Polypharmacology;2022

4. Phase I study of cediranib, an oral VEGFR inhibitor, in combination with selumetinib, an oral MEK inhibitor, in patients with advanced solid malignancies;Investigational New Drugs;2021-09-13

5. Nephrotoxicity From Molecularly Targeted Chemotherapeutic Agents;Advances in Chronic Kidney Disease;2021-09